Logo image of CARL

CARLSMED INC (CARL) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CARL - US14280C1053 - Common Stock

12.69 USD
-0.18 (-1.4%)
Last: 1/9/2026, 8:00:01 PM
Fundamental Rating

3

CARL gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 185 industry peers in the Health Care Equipment & Supplies industry. The financial health of CARL is average, but there are quite some concerns on its profitability. CARL is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CARL has reported negative net income.
CARL Yearly Net Income VS EBIT VS OCF VS FCFCARL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

CARL's Return On Assets of -34.45% is on the low side compared to the rest of the industry. CARL is outperformed by 61.08% of its industry peers.
CARL's Return On Equity of -43.55% is in line compared to the rest of the industry. CARL outperforms 52.97% of its industry peers.
Industry RankSector Rank
ROA -34.45%
ROE -43.55%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CARL Yearly ROA, ROE, ROICCARL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2023 2024 0 500 1K

1.3 Margins

With an excellent Gross Margin value of 74.35%, CARL belongs to the best of the industry, outperforming 83.78% of the companies in the same industry.
CARL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.35%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CARL Yearly Profit, Operating, Gross MarginsCARL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2023 2024 0 -50 -100

More info and screens

6

2. Health

2.1 Basic Checks

CARL does not have a ROIC to compare to the WACC, probably because it is not profitable.
CARL has about the same amout of shares outstanding than it did 1 year ago.
The debt/assets ratio for CARL has been reduced compared to a year ago.
CARL Yearly Shares OutstandingCARL Yearly Shares OutstandingYearly Shares Outstanding 2023 2024 5M 10M 15M 20M 25M
CARL Yearly Total Debt VS Total AssetsCARL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

An Altman-Z score of 6.65 indicates that CARL is not in any danger for bankruptcy at the moment.
CARL's Altman-Z score of 6.65 is amongst the best of the industry. CARL outperforms 81.62% of its industry peers.
CARL has a Debt/Equity ratio of 0.14. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of CARL (0.14) is better than 60.54% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Altman-Z 6.65
ROIC/WACCN/A
WACC9.76%
CARL Yearly LT Debt VS Equity VS FCFCARL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2023 2024 0 20M -20M -40M

2.3 Liquidity

A Current Ratio of 12.03 indicates that CARL has no problem at all paying its short term obligations.
CARL's Current ratio of 12.03 is amongst the best of the industry. CARL outperforms 95.14% of its industry peers.
CARL has a Quick Ratio of 11.91. This indicates that CARL is financially healthy and has no problem in meeting its short term obligations.
CARL's Quick ratio of 11.91 is amongst the best of the industry. CARL outperforms 96.22% of its industry peers.
Industry RankSector Rank
Current Ratio 12.03
Quick Ratio 11.91
CARL Yearly Current Assets VS Current LiabilitesCARL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2023 2024 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

CARL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -31.49%.
Looking at the last year, CARL shows a very strong growth in Revenue. The Revenue has grown by 97.16%.
EPS 1Y (TTM)-31.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)97.16%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CARL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.12% yearly.
The Revenue is expected to grow by 27.71% on average over the next years. This is a very strong growth
EPS Next Y-30.07%
EPS Next 2Y4.72%
EPS Next 3Y6.18%
EPS Next 5Y9.12%
Revenue Next Year-6.79%
Revenue Next 2Y14.49%
Revenue Next 3Y22.99%
Revenue Next 5Y27.71%

3.3 Evolution

CARL Yearly Revenue VS EstimatesCARL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 50M 100M
CARL Yearly EPS VS EstimatesCARL Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 2028 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CARL. In the last year negative earnings were reported.
Also next year CARL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CARL Price Earnings VS Forward Price EarningsCARL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CARL Per share dataCARL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.72%
EPS Next 3Y6.18%

More info and screens

0

5. Dividend

5.1 Amount

CARL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CARLSMED INC

NASDAQ:CARL (1/9/2026, 8:00:01 PM)

12.69

-0.18 (-1.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)N/A N/A
Inst Owners34.1%
Inst Owner Change0%
Ins Owners11.54%
Ins Owner Change20.2%
Market Cap337.43M
Revenue(TTM)62.51M
Net Income(TTM)-46.45M
Analysts85.45
Price Target19.99 (57.53%)
Short Float %4.18%
Short Ratio8.49
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)6.52%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-20.11%
EPS NY rev (1m)0%
EPS NY rev (3m)-7.27%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)10.03%
Revenue NY rev (1m)0%
Revenue NY rev (3m)6.4%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.4
P/FCF N/A
P/OCF N/A
P/B 3.16
P/tB 3.16
EV/EBITDA N/A
EPS(TTM)-1.83
EYN/A
EPS(NY)-1.69
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS2.35
BVpS4.01
TBVpS4.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -34.45%
ROE -43.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.35%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.03
Quick Ratio 11.91
Altman-Z 6.65
F-ScoreN/A
WACC9.76%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-31.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-30.07%
EPS Next 2Y4.72%
EPS Next 3Y6.18%
EPS Next 5Y9.12%
Revenue 1Y (TTM)97.16%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-6.79%
Revenue Next 2Y14.49%
Revenue Next 3Y22.99%
Revenue Next 5Y27.71%
EBIT growth 1Y-29.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year35.81%
EBIT Next 3Y12.12%
EBIT Next 5Y15.19%
FCF growth 1Y-45.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-45.69%
OCF growth 3YN/A
OCF growth 5YN/A

CARLSMED INC / CARL FAQ

What is the ChartMill fundamental rating of CARLSMED INC (CARL) stock?

ChartMill assigns a fundamental rating of 3 / 10 to CARL.


Can you provide the valuation status for CARLSMED INC?

ChartMill assigns a valuation rating of 0 / 10 to CARLSMED INC (CARL). This can be considered as Overvalued.


What is the profitability of CARL stock?

CARLSMED INC (CARL) has a profitability rating of 1 / 10.


What is the earnings growth outlook for CARLSMED INC?

The Earnings per Share (EPS) of CARLSMED INC (CARL) is expected to decline by -30.07% in the next year.